An Analysis of 20 Cases of Radiation-Associated Sarcoma, Including 4 Cases Treated by Carbon Ion Radiotherapy

Oncology ◽  
2021 ◽  
Author(s):  
Takahito Negishi ◽  
Akira Matsunobu ◽  
Makoto Endo ◽  
Ryouhei Yokoyama ◽  
Shuhei Kusano ◽  
...  
Keyword(s):  
Treatment Options ◽  
The Other ◽  
Carbon Ion Radiotherapy ◽  
Spindle Cell Sarcoma ◽  
Malignant Neoplasms ◽  
Nerve Sheath Tumor ◽  
Pharyngeal Cancer ◽  
Carbon Ion ◽  
Disease Free ◽  
Free Status

Introduction Radiation-associated sarcoma (RAS) is one of the most life-threatening complications associated with the treatment of malignant neoplasms. Because all RAS patients have a history of radiotherapy, there have been no effective treatment options when RAS is not completely resected. Methods We retrospectively reviewed 20 RAS patients, including 4 unresectable cases treated by carbon ion radiotherapy (CIRT). Results The primary diseases targeted by radiotherapy included malignant lymphoma (n=4), cervical cancer (n=3), pharyngeal cancer (n=3), breast cancer (n=2), lung cancer (n=1), rectal cancer (n=1), maxillary cancer (n=1), synovial sarcoma (n=1), and benign neoplasms (n=4). The histological diagnoses of RAS included osteosarcoma (n=8), leiomyosarcoma (n=3), undifferentiated pleomorphic sarcoma (n=3), rhabdomyosarcoma (n=1), angiosarcoma (n=1), malignant peripheral nerve sheath tumor (n=1), spindle cell sarcoma NOS (n=1), and sarcoma not further specified (n=2). The median survival time from the diagnosis of RAS was 26 months. Eleven patients underwent surgery. Five of these patients achieved a continuous disease free status or showed no evidence disease. Four patients underwent CIRT. One of these patients with leiomyosarcoma achieved a continuous disease free status, and the other patient with osteosarcoma achieved a partial response. On the other hand, 2 patients experienced Grade 3 toxicities that required surgical treatment. Conclusion RAS originates from various types of diseases that are treated by radiotherapy and shows diverse pathological features. Complete resection achieves a good prognosis. CIRT can be an effective and feasible option for unresectable RAS.

scholarly journals Primary spindle cell sarcoma of the heart treated with carbon-ion radiotherapy: Case report

2020 ◽  
Vol 76 ◽  
pp. 1-4
Author(s):  
Ikuko Shibasaki ◽  
Shigeru Toyoda ◽  
Yusuke Takei ◽  
Masayuki Chida ◽  
Hirotsugu Fukuda
Keyword(s):  
Case Report ◽  
Spindle Cell ◽  
Carbon Ion Radiotherapy ◽  
Spindle Cell Sarcoma ◽  
Cell Sarcoma ◽  
Carbon Ion

Carbon-ion Radiotherapy for Esophageal Cancer

2010 ◽  
Vol 61 (2) ◽  
pp. 67-67
Author(s):  
S. Yasuda ◽  
S. Yamada ◽  
H. Imada ◽  
M. Shinoto ◽  
J. Mizoe ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

Unresectable Chondrosarcomas Treated With Carbon Ion Radiotherapy: Relationship Between Dose-averaged Linear Energy Transfer and Local Recurrence

2020 ◽  
Vol 40 (11) ◽  
pp. 6429-6435
Author(s):  
SHINNOSUKE MATSUMOTO ◽  
SUNG HYUN LEE ◽  
REIKO IMAI ◽  
TAKU INANIWA ◽  
NARUHIRO MATSUFUJI ◽  
...  
Keyword(s):  
Energy Transfer ◽  
Local Recurrence ◽  
Linear Energy Transfer ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

scholarly journals Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 339
Author(s):  
Giulia Buizza ◽  
Chiara Paganelli ◽  
Emma D’Ippolito ◽  
Giulia Fontana ◽  
Silvia Molinelli ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Skull Base ◽  
Local Control ◽  
Tumour Progression ◽  
Risk Groups ◽  
Carbon Ion Radiotherapy ◽  
Survival Models ◽  
Carbon Ion ◽  
Combined Models ◽  
Skull Base Chordoma

Skull-base chordoma (SBC) can be treated with carbon ion radiotherapy (CIRT) to improve local control (LC). The study aimed to explore the role of multi-parametric radiomic, dosiomic and clinical features as prognostic factors for LC in SBC patients undergoing CIRT. Before CIRT, 57 patients underwent MR and CT imaging, from which tumour contours and dose maps were obtained. MRI and CT-based radiomic, and dosiomic features were selected and fed to two survival models, singularly or by combining them with clinical factors. Adverse LC was given by in-field recurrence or tumour progression. The dataset was split in development and test sets and the models’ performance evaluated using the concordance index (C-index). Patients were then assigned a low- or high-risk score. Survival curves were estimated, and risk groups compared through log-rank tests (after Bonferroni correction α = 0.0083). The best performing models were built on features describing tumour shape and dosiomic heterogeneity (median/interquartile range validation C-index: 0.80/024 and 0.79/0.26), followed by combined (0.73/0.30 and 0.75/0.27) and CT-based models (0.77/0.24 and 0.64/0.28). Dosiomic and combined models could consistently stratify patients in two significantly different groups. Dosiomic and multi-parametric radiomic features showed to be promising prognostic factors for LC in SBC treated with CIRT.

scholarly journals Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy: a case report

2021 ◽  
Author(s):  
Hiroki Kobayashi ◽  
Satoshi Kobayashi ◽  
Masaki Shiota ◽  
Dai Takamatsu ◽  
Tatsuro Abe ◽  
...  
Keyword(s):  
Case Report ◽  
Radical Prostatectomy ◽  
Carbon Ion Radiotherapy ◽  
Robot Assisted ◽  
Carbon Ion

scholarly journals Development of a Safe and Highly Efficient Inactivated Vaccine Candidate against Lumpy Skin Disease Virus

Vaccines ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 4
Author(s):  
Janika Wolff ◽  
Tom Moritz ◽  
Kore Schlottau ◽  
Donata Hoffmann ◽  
Martin Beer ◽  
...  
Keyword(s):  
Skin Disease ◽  
Animal Health ◽  
Vaccine Virus ◽  
Lumpy Skin Disease ◽  
Virus Shedding ◽  
Clinical Protection ◽  
Inactivated Vaccines ◽  
Disease Free ◽  
World Organisation ◽  
Free Status

Capripox virus (CaPV)-induced diseases (lumpy skin disease, sheeppox, goatpox) are described as the most serious pox diseases of livestock animals, and therefore are listed as notifiable diseases under guidelines of the World Organisation for Animal Health (OIE). Until now, only live-attenuated vaccines are commercially available for the control of CaPV. Due to numerous potential problems after vaccination (e.g., loss of the disease-free status of the respective country, the possibility of vaccine virus shedding and transmission as well as the risk of recombination with field strains during natural outbreaks), the use of these vaccines must be considered carefully and is not recommended in CaPV-free countries. Therefore, innocuous and efficacious inactivated vaccines against CaPV would provide a great tool for control of these diseases. Unfortunately, most inactivated Capripox vaccines were reported as insufficient and protection seemed to be only short-lived. Nevertheless, a few studies dealing with inactivated vaccines against CaPV are published, giving evidence for good clinical protection against CaPV-infections. In our studies, a low molecular weight copolymer-adjuvanted vaccine formulation was able to induce sterile immunity in the respective animals after severe challenge infection. Our findings strongly support the possibility of useful inactivated vaccines against CaPV-infections, and indicate a marked impact of the chosen adjuvant for the level of protection.

scholarly journals Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yang Li ◽  
Yoshiki Kubota ◽  
Masahiko Okamoto ◽  
Shintaro Shiba ◽  
Shohei Okazaki ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Carbon Ion Radiotherapy ◽  
Adaptive Planning ◽  
Carbon Ion ◽  
Single Beam ◽  
Original Plan ◽  
Image Registration Algorithm ◽  
Passive Scattering ◽  
Accumulated Dose ◽  
Dose Difference

Abstract Background Daily anatomical deviations may distort the dose distribution in carbon ion radiotherapy (CIRT), which may cause treatment failure. Therefore, this study aimed to perform re-planning to maintain the dose coverage in patients with pancreatic cancer with passive scattering CIRT. Methods Eight patients with pancreatic cancer and 95 daily computed tomography (CT) sets were examined. Two types of adaptive plans based on new range compensators (RCs) (AP-1) and initial RCs (AP-2) were generated. In AP-2, each beam was optimized by manually adjusting the range shifter thickness and spread-out Bragg peak size to make dose reduction by < 3% of the original plan. Doses of the original plan with bone matching (BM) and tumor matching (TM) were examined for comparison. We calculated the accumulated dose using the contour and intensity-based deformable image registration algorithm. The dosimetric differences in respect to the original plan were compared between methods. Results Using TM and BM, mean ± standard deviations of daily CTV V95 (%) difference from the original plan was − 5.1 ± 6.2 and − 8.8 ± 8.8, respectively, but 1.2 ± 3.4 in AP-1 and − 0.5 ± 2.1 in AP-2 (P < 0.001). AP-1 and AP-2 enabled to maintain a satisfactory accumulated dose in all patients. The dose difference was 1.2 ± 2.8, − 2,1 ± 1.7, − 7.1 ± 5.2, and − 16.5 ± 15.0 for AP-1, AP-2, TM, and BM, respectively. However, AP-2 caused a dose increase in the duodenum, especially in the left–right beam. Conclusions The possible dose deterioration should be considered when performing the BM, even TM. Re-planning based on single beam optimization in passive scattering CIRT seems an effective and safe method of ensuring the treatment robustness in pancreatic cancer. Further study is necessary to spare healthy tissues, especially the duodenum.

scholarly journals Carbon ion radiotherapy for prostate cancer with bladder invasion

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yuhei Miyasaka ◽  
Hidemasa Kawamura ◽  
Hiro Sato ◽  
Nobuteru Kubo ◽  
Tatsuji Mizukami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Locally Advanced ◽  
Therapeutic Benefit ◽  
Carbon Ion Radiotherapy ◽  
Safety And Efficacy ◽  
Carbon Ion ◽  
Grade 3 ◽  
Bladder Invasion

Abstract Background The optimal management of clinical T4 (cT4) prostate cancer (PC) is still uncertain. At our institution, carbon ion radiotherapy (CIRT) for nonmetastatic PC, including tumors invading the bladder, has been performed since 2010. Since carbon ion beams provide a sharp dose distribution with minimal penumbra and have biological advantages over photon radiotherapy, CIRT may provide a therapeutic benefit for PC with bladder invasion. Hence, we evaluated CIRT for PC with bladder invasion in terms of the safety and efficacy. Methods Between March 2010 and December 2016, a total of 1337 patients with nonmetastatic PC received CIRT at a total dose of 57.6 Gy (RBE) in 16 fractions over 4 weeks. Among them, seven patients who had locally advanced PC with bladder invasion were identified. Long-term androgen-deprivation therapy (ADT) was also administered to these patients. Adverse events were graded according to the Common Terminology Criteria for Adverse Event version 5.0. Results At the completion of our study, all the patients with cT4 PC were alive with a median follow-up period of 78 months. Grade 2 acute urinary disorders were observed in only one patient. Regarding late toxicities, only one patient developed grade 2 hematuria and urinary urgency. There was no grade 3 or worse toxicity, and gastrointestinal toxicity was not observed. Six (85.7%) patients had no recurrence or metastasis. One patient had biochemical and local failures 42 and 45 months after CIRT, respectively. However, the recurrent disease has been well controlled by salvage ADT. Conclusions Seven patients with locally advanced PC invading the bladder treated with CIRT were evaluated. Our findings seem to suggest positive safety and efficacy profiles for CIRT.

Sign in / Sign up

Export Citation Format

Share Document